SLLN-15 Autophagy inducer RGNCY-0102
Per 10 mg
SLLN-15 is a potent autophagy enhancer that selectively activated cytostatic macroautophagy/autophagy in TNBC preclinical models. SLLN-15 induced a dose-dependent anti-proliferative activity in TNBC cell lines MDA-MB-231 and BT-20 by inducing autophagy and autophagic flux. This was associated with a selective inhibition of AKT-MTOR signalling. In contrast, a known autophagy inducer and MTOR inhibitor, rapamycin, did not replicate SLLN-15's effect on TNBC cells. SSLN-15-induced inhibition of cancer cell proliferation was also shown to be autophagy-dependent as siRNA-mediated targeting of autophagy regulators (BECNI, ATG and ATG7) significantly protected against SLLN-15-induced inhibition of cancer cell proliferation. In SLLN-15-induced autophagy in TNBC cells was associated with decreased AUKRA expression, decreased AKT phosphorylation and subsequent blockage of AKT-MTOR pathway. Oral SLLN-15 was also shown to have potent anticancer and anti-metastatic activity in vivo in mice bearing TNBC.
Systematic Name: (S)-N2-(4-selenomorpholinophenyl)-N6-(tetrahydroselenophen-3-yl)-9H-purine-2,6-diamine
Mol Wt: 507.36
A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Chang CH. et al. Autophagy. 2019 Mar 1:1-15. doi: 10.1080/15548627.2019.1582951. [Epub ahead of print].
There are no uploaded files